Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on November 25, 2008
JNCI Journal of the National Cancer Institute 2008 100(23):1667-1669; doi:10.1093/jnci/djn429
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/23/1667    most recent
djn429v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

K-Ras Mutations Are Changing Practice in Advanced Colorectal Cancer

Caroline McNeil

The first 150 words of the full text of this article appear below.

Last month, an expert panel said that patients with advanced colorectal cancer should not be treated with cetuximab or panitumumab if their tumors have mutations in the K-Ras oncogene. The major new recommendation from the National Comprehensive Cancer Network (NCCN), based on a consensus of experts at 21 comprehensive cancer centers across the United States, reflects a change in practice that is already affecting thousands of patients, altering reimbursement policies, and changing the design of clinical trials.

"This really is a sea change in practice," said Leonard Saltz, M.D., a professor of medicine at Memorial Sloan-Kettering Cancer Center in New York and a member of the NCCN colorectal cancer panel.

Cetuximab and panitumumab are monoclonal antibodies targeted at epidermal growth factor receptors (EGFRs) on tumor cells. They work by blocking the growth signals that the receptor sends to the cell nucleus. In trials, both have improved progression-free survival in metastatic . . . [Full Text of this Article]

Clinical Effect

Future Research


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?